State

Nebraska product recalls

73,833 recalls have nationwide distribution and so reach Nebraska. 4,580 additional recalls listed Nebraska specifically in their distribution scope.

What the numbers show

Total: 4,580
Critical: 713
Severe: 1,345
Most recent: 2026-10-28

Of the 4,580 recalls naming Nebraska we have scored against our rubric, 713 (16%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 1,345 (29%) are Severe.

Which agencies issued them

These figures cover only the 4,580 recalls whose distribution notice names Nebraska specifically. The 73,833 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

57826–57850 of 78413

SevereFDA (Drugs)·D-920-2015·2015-04-29
Terbinafine Base Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Terbinafine Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Terbinafine Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-754-2015·2015-04-29
Attix Pharmaceuticals Recalls Levetiracetam Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Levetiracetam active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Levetiracetam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-918-2015·2015-04-29
Attix Pharmaceuticals Recalls Temozolomide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Temozolomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Temozolomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-854-2015·2015-04-29
Attix Pharmaceuticals Recalls Prazosin HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Prazosin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Prazosin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-933-2015·2015-04-29
Tobramycin Sulfate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Tobramycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Tobramycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-629-2015·2015-04-29
Attix Pharmaceuticals Recalls Diclofenac Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Diclofenac Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Diclofenac Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-580-2015·2015-04-29
Attix Pharmaceuticals Recalls Chloroxine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Chloroxine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Chloroxine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-802-2015·2015-04-29
Attix Pharmaceuticals Recalls Misoprostol API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Misoprostol 1% active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Misoprostol 1% active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-955-2015·2015-04-29
Attix Pharmaceuticals Recalls Voriconazole Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Voriconazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Voriconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-566-2015·2015-04-29
Attix Pharmaceuticals Recalls Cefadroxil Monohydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cefadroxil Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cefadroxil Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-607-2015·2015-04-29
Attix Pharmaceuticals Recalls Cyclosporine A Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cyclosporine A active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cyclosporine A active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-559-2015·2015-04-29
Attix Pharmaceuticals Recalls Capecitabine Due to Penicillin Cross Contamination
Attix Pharmaceuticals is recalling capecitabine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Capecitabine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-501-2015·2015-04-29
Attix Pharmaceuticals Recalls Acyclovir Sodium Due to Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Acyclovir Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Acyclovir Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-810-2015·2015-04-29
Attix Pharmaceuticals Recalls Mycophenolate Mofetil Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Mycophenolate Mofetil active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Mycophenolate Mofetil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-568-2015·2015-04-29
Attix Pharmaceuticals Recalls Cefixime API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cefixime active pharmaceutical ingredient (API) due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cefixime active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-750-2015·2015-04-29
Leflunomide API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Leflunomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Leflunomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-787-2015·2015-04-29
Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Methscopolamine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-640-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxorubicin HCI Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Doxorubicin HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Doxorubicin HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-641-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxycycline HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Doxycycline HCI active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Doxycycline HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-783-2015·2015-04-29
Attix Pharmaceuticals Recalls Methazolamide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Methazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Methazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Devices)·Z-1513-2015·2015-04-29
CSA Medical truFreeze Console Cryosurgical Unit Recalled for Excess Liquid Nitrogen Delivery
CSA Medical is recalling 82 truFreeze Console cryosurgical units because they may deliver excessive liquid nitrogen, posing risks of stricture, scarring, bradycardia, or pneumothorax.
Product
CSA Medical truFreeze Console- Cryosurgical Unit Cryogenic Surgical Device Model: CC3-01
Category
Medical Device
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-564-2015·2015-04-29
Attix Pharmaceuticals Recalls Carboxymethyl Dextran Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Carboxymethyl Dextran active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Carboxymethyl Dextran active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-610-2015·2015-04-29
Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dantrolene Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Dantrolene Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-744-2015·2015-04-29
Attix Pharmaceuticals Recalls Ketotifen Fumarate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Ketotifen Fumarate active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Ketotifen Fumarate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-845-2015·2015-04-29
Attix Pharmaceuticals Recalls Piroxicam Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling piroxicam active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Piroxicam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide